Abstracts tagged "axial spondyloarthritis"

Abstract Number: 2521 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes
Pervin Sanci¹, Gokce Kenar², Berrin Zengin², Sadettin Uslu³, Aydan Koken³, Handan Yarkan³, Gerçek Can³, Merih Birlik³ and Fatos Onen², ¹Internal Medicine, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: An increased prevalence of metabolic syndrome (MetS) has been reported in psoriatic arthritis (PsA) suggesting an association between the inflammation and MetS. The aim…
Abstract Number: 1315 • 2017 ACR/ARHP Annual Meeting
Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode
Frauke Förger¹, Stephanie van den Brandt², Astrid Zbinden³, Monika Ostensen³ and Peter M. Villiger³, ¹Inselspital, University of Bern, Bern, Switzerland, ²Clinical Immunology and Rheumatology, University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: To analyze pregnancy complications, pregnancy outcome and delivery mode in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).Methods: Patients with RA and axSpA…
Abstract Number: 2803 • 2017 ACR/ARHP Annual Meeting
Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment
Joachim Sieper¹, Robert B.M. Landewé², Marina N. Magrey³, Jaclyn K. Anderson⁴, Sheng Zhong⁴, Xin Wang⁴ and Apinya Lertratanakul⁴, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²University of Amsterdam, Amsterdam, Netherlands, ³Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Sustained remission is an important treatment goal in patients (pts) with non-radiographic axial SpA (nr-axSpA). Factors predicting successful remission maintenance are unknown. We sought…
Abstract Number: 1503 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Axial Spondyloarthritis in Israel
Sara Borok Lev-Ran¹, Hagit Sarvagyl-Maman², Victoria Furer³, Sara Pel⁴, Iddo Drukman⁵, Gideon Flusser⁵ and Ori Elkayam⁶, ¹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, ²Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Sourasky Medical Center, Tel Aviv, Israel, ⁵Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose: The concept of axial Spondyloarthritis (SpA) as defined by the ASAS criteria is relatively new. While the prevalence of Ankylosing spondylitis is around 0.5%,…
Abstract Number: 1507 • 2017 ACR/ARHP Annual Meeting
Comparison of the Clinical and Imaging Arms of the Assessment of Spondyloarthritis International Society Classification Criteria and Parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Atul A. Deodhar³, Helena Marzo-Ortega⁴, Robert G. Lambert⁵, Mei Li⁶, Xin Wang⁶ and Jaclyn K. Anderson⁶, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴NIHR LBRC, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom, ⁵University of Alberta, Edmonton, AB, Canada, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) recommendations for use of TNF inhibitors (TNFi) in axial SpA include active disease and a positive expert opinion,…
Abstract Number: 1513 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Atul A. Deodhar¹, Theresa Hunter², David Sandoval Calderon³, Steve Lobosco⁴, Rachel Moon⁴ and Gary Milligan⁵, ¹Oregon Health & Science University, Portland, OR, ²Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was…
Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Maxime Dougados¹, Philip J Mease², Joachim Sieper³, Peter C. Taylor⁴, Natasha de Peyrecave⁵, Tommi Nurminen⁶ and Jürgen Braun⁷, ¹Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Charité University Hospital, Berlin, Germany, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…
Abstract Number: 1566 • 2017 ACR/ARHP Annual Meeting
Elevated IL-1 Expression Levels in Mesenchymal Stem Cells Derived from Spondyloarthitis Patients Might be Linked to Increased Osteoblast Mineralization
Gerlinde Layh-Schmitt¹, Breanna Nguyen¹, Emily Lazowick¹, Stephen R. Brooks² and Robert Colbert¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS/NIH, Biodata Mining & Discovery, Bethesda, MD
Background/Purpose: Axial spondyloarthritis (AxSpA) is an immune–mediated inflammatory disease involving the spine and sacroiliac joint. AxSpA is characterized by vertebral trabecular bone loss and progressive…
Abstract Number: 1573 • 2017 ACR/ARHP Annual Meeting
In Vivo Phosphorylation of p38 in Monocytes Is Enhanced in Patients with Axial Spondyloarthritis (axSpA) at the Time of Diagnosis
Antti Kuuliala^1,2, Krista Kuuliala^1,3, Riitta Koivuniemi^2,4, Mari Hämäläinen⁵, Eeva Moilanen⁶, Hannu Kautiainen⁷, Heikki Repo^1,3 and Marjatta Leirisalo-Repo^2,4, ¹Bacteriology and Immunology, University of Helsinki, Helsinki, Finland, ²Rheumatology, Helsinki University Hospital, Helsinki, Finland, ³Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, ⁶The Immunopharmacology Research Group, Faculty of Medicine and Life Sciences, University of Tampere and Tampere University Hospital, Tampere, Finland, Tampere, Finland, ⁷Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Host response to microbes is considered to contribute to the pathogenesis to axSpA and other HLA-B27 associated diseases. The p38 MAP kinase pathway plays…
Abstract Number: 687 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Atul A. Deodhar¹, Maxime Dougados², Robert Landewé³, Joachim Sieper⁴, Walter Maksymowych⁵, Martin Rudwaleit⁶, Filip van Den Bosch⁷, Jürgen Braun⁸, Philip J Mease⁹, Alan Kivitz¹⁰, Jessica Walsh¹¹, Owen Davies¹², Bengt Hoepken¹³, Luke Peterson¹⁴ and Désirée van der Heijde¹⁵, ¹Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Academic Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, Netherlands, ⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Klinikum Bielefeld and Charité – University Medicine Berlin, Berlin, Germany, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰Altoona Center for Clinical Research, Duncansville, PA, ¹¹Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Monheim, Germany, ¹⁴UCB Pharma, Raleigh, NC, ¹⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RAPID-axSpA (NCT01087762) investigated the efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic…
Abstract Number: 2745 • 2016 ACR/ARHP Annual Meeting
Adult Axial Spondyloarthritis Screening and Referral Practices Amongst Primary Care Physicians, Physiotherapists, Chiropractors and Nurse Practitioners: Results from a Qualitative Study
Laura Passalent^1,2, Leslie Soever^2,3, Kathleen Bednis¹, Christopher Hawke^1,4, Andrew Bidos^5,6, Jeff Bloom^7,8, Y. Raja Rampersaud^6,8, Nigil Haroon^9,10 and Robert D Inman^8,9, ¹Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ²Physical Therapy, University of Toronto, Toronto, ON, Canada, ³MSK, Geriatrics and Cardiac Rehab Programs, University Health Network, Toronto, ON, Canada, ⁴Department of Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁵Health Quality Programs - ISAEC, University Health Network, Toronto, ON, Canada, ⁶Orthopaedics, Toronto Western Hospital, Toronto, ON, Canada, ⁷Family Medicine, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ¹⁰Rheumatology, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: For the axial spondyloarthritis (SpA) population, early recognition is crucial in preventing major morbidity. Despite this, there exists an unacceptably long delay between the…
Abstract Number: 688 • 2016 ACR/ARHP Annual Meeting
Spondyloarthritis Research Consortium of Canada (SPARCC) Baseline MRI SI Joint Score ≥2 Better Predicts Response to Golimumab Than Does Assessment of Spondyloarthritis International Society (ASAS) MRI Positivity in Nonradiographic Axial Spondyloarthritis
Walter Maksymowych¹, Anjela Tzontcheva², George Philip², Gina Bergman², Susan Huyck² and Sean P. Curtis², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Golimumab (GLM) was shown to be effective for nonradiographic axial spondyloarthritis (nr-axSpA) in a randomized, double-blind, placebo-controlled, phase 3 study (GO-AHEAD; NCT01453725).1 The SPondyloArthritis…
Abstract Number: 2754 • 2016 ACR/ARHP Annual Meeting
Self-Reported Physical Activity Questionnaire in Axial Spondyloarthritis: Modification of the Squash
Fiona Maas¹, Anna Jetske Baron^1,2, Freke Wink³, Reinhard Bos³, Yvo Kamsma², Hendrika Bootsma⁴, Suzanne Arends^1,3 and Anneke Spoorenberg^1,3, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: Improvement of physical function and physical activity are important goals in the management of axial spondyloarthritis (axSpA). Although physical function is included in the…
Abstract Number: 697 • 2016 ACR/ARHP Annual Meeting
Does Axial Spondyloarthritis Phenotype Correlate with Imaging Morphotype?
Xenofon Baraliakos¹, Annette Szumski², Heather Jones³ and Lianne S. Gensler⁴, ¹Rheumazentrum, Ruhr University, Bochum, Germany, ²inVentiv Health, Princeton, NJ, ³Inflammation & Immunology, Pfizer, Collegeville, PA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Traditionally, radiographic imaging was used to describe morphological differences between various types of axial SpA (axSpA). MRI has advanced understanding of disease, enabled earlier…
Abstract Number: 2779 • 2016 ACR/ARHP Annual Meeting
Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis
Maxime Dougados¹, Desiree van der Heijde², Wen-Chan Tsai³, Diego Saaibi⁴, Randi Bonin⁵, Lisa Marshall⁶, Heather Jones⁷, Ronald Pedersen⁸, Bonnie Vlahos⁹ and Miriam Tarallo¹⁰, ¹Rheumatology, Paris Descartes University, Paris, France, ²Leiden University Medical Center, Leiden, Netherlands, ³Kaohsiung Medical University, Kaohsiung City, Taiwan, ⁴MEDICITY S.A.S, Bucaramanga, Colombia, ⁵Clinical Affairs, Pfizer, Collegeville, PA, ⁶Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁷Inflammation & Immunology, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁰GHV, Pfizer, Rome, Italy
Background/Purpose: Few studies have evaluated the relationship between disease activity/clinical response and patient-reported outcomes (PROs) of pain, fatigue, health-related quality of life (HRQoL), and work…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].